KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cme (CME) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Cme (CME) over the last 17 years, with Q3 2025 value amounting to 64.97%.

  • Cme's EBITDA Margin fell 14500.0% to 64.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 66.25%, marking a year-over-year increase of 11500.0%. This contributed to the annual value of 64.13% for FY2024, which is 25500.0% up from last year.
  • Latest data reveals that Cme reported EBITDA Margin of 64.97% as of Q3 2025, which was down 14500.0% from 68.36% recorded in Q2 2025.
  • Over the past 5 years, Cme's EBITDA Margin peaked at 69.13% during Q1 2025, and registered a low of 55.06% during Q4 2021.
  • Its 5-year average for EBITDA Margin is 63.19%, with a median of 63.63% in 2023.
  • Within the past 5 years, the most significant YoY rise in Cme's EBITDA Margin was 81800bps (2021), while the steepest drop was -45300bps (2021).
  • Quarter analysis of 5 years shows Cme's EBITDA Margin stood at 55.06% in 2021, then increased by 0bps to 55.33% in 2022, then grew by 8bps to 59.97% in 2023, then increased by 4bps to 62.09% in 2024, then grew by 5bps to 64.97% in 2025.
  • Its EBITDA Margin stands at 64.97% for Q3 2025, versus 68.36% for Q2 2025 and 69.13% for Q1 2025.